Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, Shanxi, China; Shanxi Key Laboratory of Active Constituents Research and Utilization of TCM, Taiyuan, 030006, Shanxi, China.
Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, Shanxi, China; Shanxi Key Laboratory of Active Constituents Research and Utilization of TCM, Taiyuan, 030006, Shanxi, China.
J Ethnopharmacol. 2021 Mar 25;268:113549. doi: 10.1016/j.jep.2020.113549. Epub 2020 Nov 3.
Xiaoyaosan (XYS), a classic description, has a history of thousands of years for treating depression through invigorating the liver and strengthening the spleen, which have been verified both clinically and experimentally. However, explanation of its underlying mechanisms remains a great challenge.
The mechanisms of XYS in treating depression were investigated, with emphasis on the important biomarkers, targets and pathways.
In this study, taking the targeted organ of depression, hippocampus, as the object, a combination of GC-MS based metabolomics and network pharmacology was established to illustrate the abnormality of metabolic characteristics of hippocampus of depression rats and to demonstrate the antidepressant mechanisms of XYS. Hippocampal metabolomics demonstrated potential metabolites involving in the antidepressant effects of XYS, as well as the corresponding metabolic pathways. Network pharmacology screened the potential ingredients and the targets of XYS against depression.
Metabolomics revealed that XYS significantly regulated the abnormal levels of lactic acid, glycerol, glutamine, glutamic acid, hypoxanthine, myo-inositol and cholesterol, which involved in the D-glutamine and D-glutamate metabolism, arginine biosynthesis and alanine, aspartate and glutamate metabolism. Network pharmacology showed that XYS exhibited anti-depression effects through paeoniflorin, quercetin, licochalcone a, naringenin, β-sitosterol, formononetin and kaempferol acting on interleukin-6 (IL6), mitogen-activated protein kinase 1 (MAPK1), signal transducer and activator of transcription 3 (STAT3) and transcription factor AP-1 (JUN).
Based on hippocampal metabolomics and network pharmacology, this study proved that the actions of XYS in treating depression depend on multi-components, multi-targets and multi-pathways, the unique characteristics of TCMs.
逍遥散(XYS)作为经典的方剂,具有通过疏肝健脾治疗抑郁症的千年历史,在临床和实验中均得到了验证。然而,其作用机制的解释仍然是一个巨大的挑战。
本研究旨在探讨 XYS 治疗抑郁症的作用机制,重点关注重要的生物标志物、靶点和途径。
在这项研究中,以抑郁症的靶向器官——海马体为对象,建立了基于 GC-MS 的代谢组学和网络药理学相结合的方法,以说明抑郁症大鼠海马体代谢特征的异常,并展示 XYS 的抗抑郁作用机制。海马体代谢组学证明了涉及 XYS 抗抑郁作用的潜在代谢物以及相应的代谢途径。网络药理学筛选了 XYS 治疗抑郁症的潜在成分和靶点。
代谢组学揭示,XYS 能显著调节乳酸、甘油、谷氨酰胺、谷氨酸、次黄嘌呤、肌醇和胆固醇等异常水平,这些代谢物涉及 D-谷氨酰胺和 D-谷氨酸代谢、精氨酸生物合成以及丙氨酸、天冬氨酸和谷氨酸代谢。网络药理学表明,XYS 通过作用于白细胞介素 6(IL6)、丝裂原激活蛋白激酶 1(MAPK1)、信号转导和转录激活因子 3(STAT3)和转录因子 AP-1(JUN),表现出抗抑郁作用,这些靶点由芍药苷、槲皮素、甘草素 A、柚皮苷、β-谷甾醇、芒柄花素和山奈酚等成分实现。
基于海马体代谢组学和网络药理学,本研究证明了 XYS 治疗抑郁症的作用取决于多成分、多靶点和多途径,这是中药的独特特征。